GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Reviva Pharmaceuticals Holdings Inc (NAS:RVPH) » Definitions » Current Ratio

Reviva Pharmaceuticals Holdings (Reviva Pharmaceuticals Holdings) Current Ratio : 1.38 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Reviva Pharmaceuticals Holdings Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Reviva Pharmaceuticals Holdings's current ratio for the quarter that ended in Dec. 2023 was 1.38.

Reviva Pharmaceuticals Holdings has a current ratio of 1.38. It generally indicates good short-term financial strength.

The historical rank and industry rank for Reviva Pharmaceuticals Holdings's Current Ratio or its related term are showing as below:

RVPH' s Current Ratio Range Over the Past 10 Years
Min: 1.38   Med: 4.24   Max: 13.39
Current: 1.38

During the past 5 years, Reviva Pharmaceuticals Holdings's highest Current Ratio was 13.39. The lowest was 1.38. And the median was 4.24.

RVPH's Current Ratio is ranked worse than
77.56% of 1555 companies
in the Biotechnology industry
Industry Median: 3.72 vs RVPH: 1.38

Reviva Pharmaceuticals Holdings Current Ratio Historical Data

The historical data trend for Reviva Pharmaceuticals Holdings's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Reviva Pharmaceuticals Holdings Current Ratio Chart

Reviva Pharmaceuticals Holdings Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Current Ratio
- 6.57 13.39 1.90 1.38

Reviva Pharmaceuticals Holdings Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.90 1.97 1.29 0.41 1.38

Competitive Comparison of Reviva Pharmaceuticals Holdings's Current Ratio

For the Biotechnology subindustry, Reviva Pharmaceuticals Holdings's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Reviva Pharmaceuticals Holdings's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Reviva Pharmaceuticals Holdings's Current Ratio distribution charts can be found below:

* The bar in red indicates where Reviva Pharmaceuticals Holdings's Current Ratio falls into.



Reviva Pharmaceuticals Holdings Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Reviva Pharmaceuticals Holdings's Current Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Current Ratio (A: Dec. 2023 )=Total Current Assets (A: Dec. 2023 )/Total Current Liabilities (A: Dec. 2023 )
=23.7/17.175
=1.38

Reviva Pharmaceuticals Holdings's Current Ratio for the quarter that ended in Dec. 2023 is calculated as

Current Ratio (Q: Dec. 2023 )=Total Current Assets (Q: Dec. 2023 )/Total Current Liabilities (Q: Dec. 2023 )
=23.7/17.175
=1.38

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Reviva Pharmaceuticals Holdings  (NAS:RVPH) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Reviva Pharmaceuticals Holdings Current Ratio Related Terms

Thank you for viewing the detailed overview of Reviva Pharmaceuticals Holdings's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Reviva Pharmaceuticals Holdings (Reviva Pharmaceuticals Holdings) Business Description

Traded in Other Exchanges
N/A
Address
19925 Stevens Creek Boulevard, Suite 100, Cupertino, CA, USA, 95014
Reviva Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, respiratory, and metabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, 1) Brilaroxazine (RP5063) which is in clinical development and is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and 2) RP1208.
Executives
Purav Patel director 19925 STEVENS CREEK BLVD., SUITE 100, CUPERTINO CA 95014
Narayan Parbhu officer: Chief Financial Officer 19925 STEVENS CREEK BLVD. SUITE 100, CUPERTINO CA 95014
Beta Operators Fund, L.p. 10 percent owner 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Vedanta Associates, L.p. 10 percent owner 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Vedanta Partners, Llc 10 percent owner 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Vedanta Associates-r, Lp 10 percent owner 250 WEST 55TH STREET, STE 13D, NEW YORK NY 10019
Parag Saxena director, 10 percent owner 250 WEST 55TH STREET, SUITE 13D, NEW YORK NY 10019
Rahul Nayar 10 percent owner 250 WEST 55TH STREET, NEW YORK NY 10019
Tenzing Llc director, 10 percent owner 250 WEST 55TH STREET, NEW YORK NY 10019
Laxminarayan Bhat director, 10 percent owner, officer: President and CEO 19925 STEVENS CREEK BLVD., SUITE 100, CUPERTINO CA 95014
Leslie D. Funtleyder director C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Marc Cantillon officer: Chief Medical Officer 19925 STEVENS CREEK BLVD., SUITE 100, CUPPERTINO CA 95014
Richard A Margolin director 19925 STEVENS CREEK BLVD, SUITE 100, CUPPERTINO CA 95014
Glazer Capital, Llc 10 percent owner 250 WEST 55TH STREET, SUITE 30A, NEW YORK NY 10019
Paul J Glazer 10 percent owner 250 WEST 55TH ST, SUITE 30A, NEW YORK NY 10019

Reviva Pharmaceuticals Holdings (Reviva Pharmaceuticals Holdings) Headlines

From GuruFocus

Reviva Pharmaceuticals to Present at the 2023 BIO CEO and Investor Conference

By Stock market mentor Stock market mentor 01-31-2023